- Home
- Life Sciences
- Pharmaceutical
- Pharmaceutical Industry Market Research Reports in Oceania Countries, May 2013
Talk to Sam
+1 917 267 7886
Search inside this page
Publication dates
All regions
Free Market Research Guides to Download
Pharmaceutical Industry Market Research Reports in Oceania Countries, May 2013
You might be interested in: clinical trial, cancer, drug, more »
» Download Public Reports
1-30 of about 1 500 reports
Company Report: Eye Disease in Australia and India for Year 2013
- Company report
- February 2013
- 78 pages
... That combines the health, economic and social benefits of eliminating avoidable blindness and visual impairment on a global scale, to address the mission of vision 2020. As such, it differs to past studies, both ...
- Industries: Pathology
- Countries: World, Australia, India
Company Report: Drug Discovery and Development in Australia for Year 2013
- Company report
- January 2013
- 15 pages
... Is entirely flawed since it is based on the trional patent and regulatory approval processes while the time lines for drug development are defined by pre-clinical and clinical development times. Quite ...
- Industries: Drug Discovery and Development
- Countries: Australia
Company Report: Drug and Medication in Australia, The United States and Canada for Year 2013
- Company report
- February 2013
- 5 pages
- Industries: Drug and Medication
- Countries: Australia, United States, Canada
Company Report: Pathology in The United States and Australia for Year 2013
- Company report
- February 2013
- 31 pages
- by Research Paper
- Industries: Pathology
- Countries: United States, Australia
Company Report: Drug Delivery in Australia and The United States for Year 2013
- Company report
- May 2013
- 21 pages
... Of imugene platform linguet Is a proprietary drug delivery technology that improves the efficacy and safety of a diverse number of prescription and over the counter medicines. The platform technology ...
- Industries: Drug Delivery Technology
- Countries: Australia, United States
Company Report: Pathology in Indonesia and Australia for Year 2013
- Company report
- January 2013
- 8 pages
... That doesn T quite reach the level of overt depression is dysthymia. This is low-grade depression that lasts for months or even years in adults and teens. It is not as crippling as major depression but its ...
- Industries: Pathology
- Countries: Indonesia, Australia
Company Report: Pathology in Australia for Year 2013
- Company report
- January 2013
- 122 pages
... Not present this report as an independent, external review of the aids and equipment system in australia. There has been editorial input to the report through aerwg and dprwg processes. Acronyms abs ...
- Industries: Pathology
- Countries: Australia
Company Report: Drug and Medication in Australia for Year 2013
- Company report
- January 2013
- 4 pages
... Protection there would be no return on investment, and no re-investment in research, which leads to the discovery of new and innovative medicines such as new cures and treatments for cancers. Research ...
- Industries: Drug and Medication
- Countries: Australia
Australian Pharmaceutical Industries Ltd. - Company Report for Year 2013
- Company report
- January 2013
- 4 pages
... With the pharmaceutical industry, in particular, pharmacists and suppliers. We have built a strong platform for continued progress in the market in which we operate. Finally before handing over to stephen, i would like ...
- Industries: Pharmaceutical
- Countries: Australia
Company Report: Drug and Medication in Australia for Year 2013
- Company report
- January 2013
- 4 pages
... In as it appears to be trending slower over time. Patents on medicines in australia have a five year data protection for clinical trial data submitted for regulatory approval, while most other industrialised ...
- Industries: Drug and Medication
- Countries: Australia
Company Report: Pathology in Australia for Year 2013
- Company report
- January 2013
- 16 pages
... And resolve complaints in a way that is truly independent and accessible. As australia S leaders in the blindness and low vision sector, we have drawn upon our unique position to gather together and present ...
- Industries: Pathology
- Countries: Australia
Company Report: Ovarian Cancer in The United States and Australia for Year 2013
- Company report
- January 2013
- 38 pages
... Player - we are initiating coverage of prima biomed (asx: prr) with a buy recommendation and a price target of a$0.27. Company is developing an immunotherapy for ovarian cancer. While cancer vaccines ...
- Industries: Pathology
- Countries: United States, Australia
Company Report: Drug and Medication in Australia for Year 2013
- Company report
- March 2013
- 5 pages
... Placement of $170m to new and existing institutional investors 14-mar-13 qrx qrx pharma fda sets 26 august as new pdufa date for the resubmitted new drug application for moxduo-ir 15-mar-13 bne bone medical ...
- Industries: Drug and Medication
- Countries: Australia
RPD Inc. - Company Report for Year 2013
- Company report
- March 2013
- 16 pages
- by Governmental Agency
... Of professional programs and services that aim to improve consumer health outcomes. These include services to support medication management, programs to assist the pharmacy workforce, activities to support ...
- Industries: Drug and Medication
- Countries: Australia
Company Report: Vaccine in Australia and The United States for Year 2013
- Company report
- March 2013
- 21 pages
- Industries: Drug and Medication
- Countries: Australia, United States
Company Report: Pathology in Australia for Year 2013
- Company report
- March 2013
- 10 pages
- Industries: Pathology
- Countries: Australia
Company Report: Hair Loss in The United States and Australia for Year 2013
- Company report
- March 2013
- 19 pages
... Commercial and licensing deals. In addition, we view diabetic nephropathy program and future partnerships in molecular diagnostics as an upside to our current target price, with strong ip around midkine ...
- Industries: Pathology
- Countries: United States, Australia
Company Report: Drug Delivery Technology in The United States and Australia for Year 2013
- Company report
- April 2013
- 2 pages
- by Corporation
- Industries: Drug Delivery Technology
- Countries: United States, Australia
Level 3 Communications Inc. - Company Report for Year 2013
- Company report
- April 2013
- 5 pages
... Formulated diclofenac by thermis. Top international stories positive data from vertex S cystic fibrosis drug:- boston-based vertex pharmaceuticals has reported positive data from a phase-2 clinical trial ...
- Industries: Pathology
- Countries: United States, Canada, Australia
Company Report: Drug and Medication in Australia, The United States and Canada for Year 2013
- Company report
- March 2013
- 5 pages
... Commercial rollout of vitrogro in europe. Top international stories amgen reports positive phase-3 data for melanoma vaccine:- which it acquired as part of biovex that it bought two years ago for up to $1 ...
- Industries: Drug and Medication
- Countries: Australia, United States, Canada
Company Report: Drug Delivery Technology in Australia for Year 2013
- Company report
- March 2013
- 5 pages
- Industries: Drug Delivery Technology
- Countries: Australia
Company Report: Pathology in New Zealand for Year 2013
- Company report
- March 2013
- 6 pages
- Industries: Pathology
- Countries: New Zealand
The Australian Medicine Industry Brief
- Industry report
- April 2013
- 2 pages
- Industries: Drug and Medication
- Countries: Australia
Vaccine Market in Australia
- Industry report
- January 2013
- 15 pages
... First produced a vaccine To combat 1918 Spanish flu Pandemic, though at this time influenza was regarded as a bacterial disease Been producing flu vaccine in eggs since mid-1940s Current ...
- Industries: Drug and Medication
- Countries: Australia
Drug Discovery and Development in Australia and India : Innovation and Technology Trends
- Industry report
- January 2013
- 18 pages
... A common bond was a tacitly agreed permissiveness - carte blanche for whatever your vision to future progress might be. Crisis in drug discovery Opportunities: Aging population in west More ...
- Industries: Drug Discovery and Development
- Countries: Australia, India
The Australian Drug and Medication Industry
- Industry report
- March 2013
- 32 pages
... For multiple suppliers Low marginal cost of production The (relevant) policy issue is what should the subsidised price be 6 Grattan analyses Identified the 50 drug-dose combinations that are highest ...
- Industries: Drug and Medication
- Countries: Australia
Pharmaceutical Market in Australia
- Industry report
- February 2013
- 47 pages
... To hepatitis c included with hiv 3rd national hiv/aids strategy partnerships in practice - 1996 hepatitis c did not have foundation community sector which was active in hiv as a function ...
- Industries: Pathology
- Countries: Australia
Pharmaceutical in Australia : Innovation and Technology Trends
- Industry report
- February 2013
- 50 pages
... In primary healthcare: collaboration, quality, evaluation from policy to practice: implementation focus at all levels compliance: legislating pharmaceutical care pcne initiates asthma tom and oma ...
- Industries: Pharmaceutical
- Countries: Australia
Cancer Industry Analysis in Australia and The United States
- Industry report
- March 2013
- 86 pages
... In the 25-35 year old age group a recent analysis of the national cancer institute statistic showed that survival rates have not increased at all since 1975 cancer is the leading disease killer ...
- Industries: Pathology
- Countries: Australia, United States
Pharmacies and Drug Stores Sector in New Zealand
- Industry report
- April 2013
- 3 pages
... pharmacy. We are concerned because as an hcm this will usually have an extra procurement cost and be dispensed infrequently. This could result in significant loss to community pharmacy. We are aware ...
- Industries: Pharmacies and Drug Stores
- Countries: New Zealand
» Purchase Premium Reports (From $ 125 - $ 3 500)
About 400 reports
Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants
- $ 3 500
- Industry report
- April 2013
- by GBI Research
Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants ...
Reportlinker.com © Copyright 2013. All rights reserved.
